Genetic Factors Involved in Cardiomyopathies and in Cancer.
Ontology highlight
ABSTRACT: Cancer therapy-induced cardiomyopathy (CCM) manifests as left ventricular (LV) dysfunction and heart failure (HF). It is associated withparticular pharmacological agents and it is typically dose dependent, but significant individual variability has been observed. History of prior cardiac disease, abuse of toxics, cardiac overload conditions, age, and genetic predisposing factors modulate the degree of the cardiac reserve and the response to the injury. Genetic/familial cardiomyopathies (CMY) are increasingly recognized in general populations with an estimated prevalence of 1:250. Association between cardiac and oncologic diseases regarding genetics involves not only the toxicity process, but pathogenicity. Genetic variants in germinal cells that cause CMY (LMNA, RAS/MAPK) can increase susc
SUBMITTER: Sabater-Molina M
PROVIDER: S-EPMC7356401 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA